TMEM9

TMEM9 is a multiply-glycosylated late-endosomal/lysosomal transmembrane protein that couples organellar acidification to cell signaling, autophagy, and ion transport (PMID:12359240, PMID:30374053). Its central characterized activity is binding to and facilitating assembly of the vacuolar-ATPase (v-ATPase), enhancing vesicular acidification and driving lysosomal degradation of the Wnt antagonist APC; the resulting loss of APC hyperactivates Wnt/β-catenin signaling, and β-catenin in turn transactivates TMEM9 to form a positive feedback loop in colorectal cancer (PMID:30374053). This TMEM9–v-ATPase–APC axis operates across tissues, controlling hepatic regeneration and sustaining β-catenin hyperactivation in hepatocellular carcinoma, where pharmacological blockade of TMEM9-v-ATPase stabilizes APC and retains β-catenin in the cytosol (PMID:32380568); epistasis experiments place TMEM9 upstream of β-catenin in cancer cells (PMID:36596527). Through its cytosolic domain TMEM9 also binds Beclin1 via the Bcl-2-binding region, displacing Bcl-2 to activate Rab9-dependent, LC3-independent alternative autophagy, a function that requires N-glycosylation-dependent lysosomal localization (PMID:39078420). Independently, TMEM9 acts as an accessory β-subunit of CLC-family Cl-/H+ antiporters, inhibiting ClC-3 by sealing the cytosolic entrance to the Cl- pathway in a manner stabilized by PtdIns(3,5)P2, and also engaging ClC-4 and ClC-5 (PMID:40670814). In microglia TMEM9 promotes C1q-dependent complement activation and synaptic engulfment by regulating the V-ATPase subunit ATP6V0D1 (PMID:39871402).

1. 2002 Medium

   Establishing where TMEM9 resides was the first step toward any functional model; the protein was assigned to the endolysosomal system.

   Evidence TMEM9-GFP transfection in COS-1 cells with LAMP1 co-localization and glycosylation sizing by SDS-PAGE

   PMID:12359240

   Open questions at the time

   • No molecular function assigned
   • Overexpression in a single cell line may not reflect endogenous distribution
   • ER signal may reflect biosynthetic transit rather than steady-state residence
2. 2018 High

   The defining mechanistic advance: TMEM9 was shown to bind and assemble v-ATPase, driving lysosomal APC degradation and a β-catenin feedback loop, linking an endolysosomal protein to Wnt-driven colorectal cancer.

   Evidence Reciprocal Co-IP, v-ATPase assembly and acidification assays, genetic ablation, and v-ATPase inhibitor rescue in APC mouse models and patient-derived xenografts

   PMID:30374053

   Open questions at the time

   • Stoichiometry of TMEM9 within the v-ATPase complex not defined
   • Mechanism by which acidification selects APC for degradation not resolved
3. 2018 Low

   An early correlative link tied TMEM9 to inflammatory cytokine output via Wnt components, hinting at a broader signaling role beyond cancer epithelium.

   Evidence Overexpression/knockdown in TNF-α-stimulated LX-2 cells with cytokine and Wnt-component western blots

   PMID:30119033

   Open questions at the time

   • Pathway placement not dissected mechanistically
   • Single lab, correlative readouts
   • No demonstration that cytokine effect requires v-ATPase/APC axis
4. 2020 High

   Independent in vivo genetics confirmed the TMEM9-v-ATPase-APC-Wnt axis in a second tissue, showing it governs hepatic regeneration and HCC β-catenin activation.

   Evidence Tmem9 knockout mouse, pharmacological v-ATPase/lysosomal inhibition, Co-IP, and regeneration assays

   PMID:32380568

   Open questions at the time

   • Whether the same mechanism operates in non-hepatic, non-colorectal contexts not addressed
   • Direct biochemical link between TMEM9 and APC turnover not fully reconstituted
5. 2023 Medium

   Epistasis testing formally placed TMEM9 upstream of β-catenin in another cancer type, reinforcing the APC/β-catenin model.

   Evidence Loss/gain-of-function in breast cancer cells with constitutively active β-catenin-S33Y rescue and downstream marker westerns

   PMID:36596527

   Open questions at the time

   • No direct biochemical interaction shown in this system
   • Single lab
   • Does not establish v-ATPase involvement in breast cancer context
6. 2024 High

   A distinct function emerged: the TMEM9 cytosolic domain binds Beclin1 to displace Bcl-2 and trigger Rab9-dependent alternative autophagy, showing TMEM9 acts beyond v-ATPase assembly.

   Evidence Reciprocal Co-IP with Bcl-2 displacement, domain mapping, glycosylation mutants, and Rab9/LC3 colocalization with autophagy flux assays

   PMID:39078420

   Open questions at the time

   • Relationship between the autophagy role and the v-ATPase/Wnt role not integrated
   • Physiological triggers of this pathway not defined
7. 2024 Medium

   TMEM9 was linked to angiogenesis through MEK/ERK/STAT3-driven VEGF induction, expanding its pro-tumorigenic repertoire.

   Evidence Knockdown/overexpression in LUAD cells, HUVEC co-culture, VEGF neutralizing antibody and recombinant VEGF rescue, and in vivo tumor models

   PMID:38664392

   Open questions at the time

   • How a lysosomal protein activates MEK/ERK/STAT3 not mechanistically connected
   • Whether this depends on v-ATPase or Wnt activity unknown
8. 2025 High

   Structural work redefined TMEM9 as an accessory β-subunit of CLC antiporters, providing the first atomic mechanism: it seals the ClC-3 cytosolic Cl- entrance, lipid-stabilized by PtdIns(3,5)P2.

   Evidence Cryo-EM structures of the TMEM9–ClC-3 complex with biochemical interaction and PtdIns(3,5)P2 functional assays, plus ClC-4/ClC-5 interaction tests

   PMID:40670814

   Open questions at the time

   • How CLC inhibition relates to the v-ATPase acidification role is unresolved
   • Physiological consequences of ClC regulation in tissues not defined
9. 2025 Medium

   TMEM9 was tied to renal Cl-/H+ transport physiology through ClC-5 interaction, with knockdown phenocopying Dent's Disease type 1 features.

   Evidence Interactome (Co-IP/MS), knockdown in renal proximal tubule cells, endocytosis and pH measurements, and organelle morphology imaging (preprint)

   PMID:bio_10.1101_2025.11.03.686312

   Open questions at the time

   • Preprint, not peer-reviewed
   • Paradoxically enhanced acidification on TMEM9 loss is unexplained relative to the v-ATPase assembly model
   • No in vivo disease model
10. 2025 Medium

    TMEM9 was implicated in neuroimmune function, promoting C1q complement activation and microglial synapse engulfment via ATP6V0D1, an exercise-sensitive pathway in Alzheimer's models.

    Evidence 5xFAD exercise model, gain/loss-of-function in oAβ-treated BV2 cells, complement and synapse engulfment assays, and ATP6V0D1/V-ATPase westerns

    PMID:39871402

    Open questions at the time

    • Direct TMEM9–ATP6V0D1 interaction not structurally defined
    • Single lab
    • Link to the CLC and Beclin1 functions not integrated

• It remains unresolved how TMEM9's apparently opposing molecular roles — promoting v-ATPase assembly/acidification versus inhibiting CLC antiporters and the paradoxically enhanced acidification on its loss — are reconciled into a single integrated endolysosomal function.
• No unified model linking v-ATPase facilitation, CLC inhibition, and alternative autophagy
• Stoichiometry and partner selection across these complexes undefined
• Tissue-specific determinants of which function dominates unknown